Deutsche Bank Sticks to Its Buy Rating for Novo Nordisk (0QIU)
In a report released today, Emmanuel Papadakis from Deutsche Bank maintained a Buy rating on Novo Nordisk (0QIU – Research Report), with a ...
GlobalData on MSN1d
Novo Nordisk and Valo expand cardiometabolic drug partnership
Novo Nordisk has expanded its partnership with Valo Health to advance new therapies for type 2 diabetes, obesity and ...
Hosted on MSN1d
BNP PARIBAS EXANE Upgrades Novo Nordisk A (NONOF)
Fintel reports that on January 5, 2025, BNP PARIBAS EXANE upgraded their outlook for Novo Nordisk A (OTCPK:NONOF) from ...
Novo Nordisk Stock Rises as UBS Upgrades Ozempic Maker, Calls Sell-Off 'Overdone'
Novo Nordisk's U.S.-listed and domestic shares rose Wednesday after analysts from UBS upgraded the Danish drugmaker's stock ...
GEN2d
Novo Nordisk, Valo Health Ink Expanded Up-to-$4.6B AI Collaboration
Novo Nordisk and Valo Health have expanded their 16-month-old collaboration into an up-to-$4.6 billion-plus artificial ...
Novo Nordisk expands AI partnership with Valo Health for development of obesity drugs
Danish drugmaker Novo Nordisk and U.S. tech firm Valo Health said on Wednesday they were expanding their 2023 agreement to ...
Novo Nordisk Seeks to Strengthen Obesity Pipeline With Two Back-To-Back Biobuck Deals
Novo Nordisk expands collaboration with Valo Health for cardiometabolic drugs and partners with Variant Bio on metabolic ...
FierceBiotech3d
Novo Nordisk and Variant set out to find new metabolic treatments, pay communities that share genetic data
Looking to expand its legacy in metabolic conditions, Novo Nordisk has inked a multiyear research pact with Variant Bio to better understand the genetics underlying disease across diverse populatio | ...
Novo Nordisk (0QIU) Gets a Buy from J.P. Morgan
J.P. Morgan analyst Richard Vosser maintained a Buy rating on Novo Nordisk (0QIU – Research Report) today and set a price target of ...